Strategies for Predicting Response to Checkpoint Inhibitors.
- Published in:
- Current Hematologic Malignancy Reports, 2018, v. 13, n. 5, p. 383, doi. 10.1007/s11899-018-0471-9
- By:
- Publication type:
- Article
Works matching IS 15588211 AND DT 2018 AND VI 13 AND IP 5
Results: 7
1
2
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
- Published in:
- Current Hematologic Malignancy Reports, 2018, v. 13, n. 5, p. 396, doi. 10.1007/s11899-018-0470-x
- By:
- Publication type:
- Article
3
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
- Published in:
- Current Hematologic Malignancy Reports, 2018, v. 13, n. 5, p. 407, doi. 10.1007/s11899-018-0469-3
- By:
- Publication type:
- Article
4
Updates on Circulating Tumor DNA Assessment in Lymphoma.
- Published in:
- Current Hematologic Malignancy Reports, 2018, v. 13, n. 5, p. 348, doi. 10.1007/s11899-018-0468-4
- By:
- Publication type:
- Article
5
Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma.
- Published in:
- Current Hematologic Malignancy Reports, 2018, v. 13, n. 5, p. 356, doi. 10.1007/s11899-018-0467-5
- By:
- Publication type:
- Article
6
Emerging EZH2 Inhibitors and Their Application in Lymphoma.
- Published in:
- Current Hematologic Malignancy Reports, 2018, v. 13, n. 5, p. 369, doi. 10.1007/s11899-018-0466-6
- By:
- Publication type:
- Article
7
Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.
- Published in:
- Current Hematologic Malignancy Reports, 2018, v. 13, n. 5, p. 341, doi. 10.1007/s11899-018-0465-7
- By:
- Publication type:
- Article